Allink Biotherapeutics

Allink Biotherapeutics Co., Ltd. established in 2023, is a pioneering biotechnology company specializing in bispecific antibody and antibody-drug conjugates (ADCs). The company’s experienced R&D focuses on the discovery and clinical development of a diverse of FIC/BIC therapeutics. Powered by a proprietary bispecific antibody platform and novel conjugation technology, AllinkBio develops next-generation BsADCs and the independent intellectual property portfolio underpins its technological advantages in the field.